Tuberculosis profile: Thailand

Population 2022: 72 million

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	111 000 (87 000-138 000)	155 (122-193)
HIV-positive TB incidence	9 200 (6 200-13 000)	13 (8.6-18)
MDR/RR-TB incidence**	2 700 (1 500-3 800)	3.7 (2.1-5.3)
HIV-negative TB mortality	12 000 (9 500-14 000)	16 (13-20)
HIV-positive TB mortality	2 100 (1 400-2 800)	2.9 (2-4)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	1.7% (1.1-2.5)
Previously treated cases	9.7% (9.1-10)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2022	65% (52-83)
TB patients facing catastrophic total costs, 2020	30% (26-34)
TB case fatality ratio (estimated mortality/estimated incidence), 2022	12% (9-16)

TB case notifications, 2022

	-
72 274	Total new and relapse
60%	- % tested with rapid diagnostics at time of diagnosis
84%	- % with known HIV status
86%	- % pulmonary
73%	- % bacteriologically confirmed *
1%	- % children aged 0-14 years
31%	- % women (aged ≥15 years)
68%	- % men (aged ≥15 years)
73 584	Total cases notified
	Total Cases Hotmed

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	5 340	8.8%
- on antiretroviral therapy	4 689	88%

Drug-resistant TB care**, 2022

$\%$ of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	75%
$\%$ of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	81%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) **	875
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^^	874
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	50
Patients started on treatment - pre-XDR-TB or XDR-TB ^^^	48
MDR/RR-TB cases tested for resistance to any fluoroquinolone	384

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	85%	71 488
Previously treated cases, excluding relapse, registered in 2021	62%	569
HIV-positive TB cases registered in 2021	72%	5 313
MDR/RR-TB cases started on second-line treatment in 2020	72%	1 142
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020	73%	62

TB preventive treatment, 2022


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	15% (14-15)

Funding for TB

Funding for TB, 2022 (US\$ millions)	26
- % domestic funding	77%
- % international funding	23%
National TB budget, 2023 (US\$ millions)	29
- Funding source, domestic	78%
- Funding source, international	22%
- Unfunded	0%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2022

(Number)




Cases attributable to five risk factors, 2022 $_{\left(\text{Number}\right)}$



Funding for TB

(US\$ millions)



Generated 2023-12-16 by the World Health Organization (https://www.who.int/teams/global-tuberculosis-programme/data)

^{*} Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^// Includes cases with unknown previous TB treatment history
^// Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed